


CLAIMS

What is claimed is:

1. A compound having the formula:

5



or a physiologically acceptable salt thereof, wherein R¹ is a halogen.


2. The compound of Claim 1 wherein R¹ is selected from the group consisting of chloro, fluoro and bromo.

3. The compound of Claim 2 wherein R¹ is chloro.

10 4. A pharmaceutical composition comprising the compound of Claim 1 and a physiologically acceptable carrier or excipient.

15 5. A method for treating a disease characterized by pathogenic leukocyte recruitment, pathogenic leukocyte activation or pathogenic leukocyte recruitment and activation, comprising administering to a subject in need thereof an effective amount of a compound of Claim 1.

6. A compound having the structure:



or a physiologically acceptable salt thereof, wherein R¹ is a halogen.

7. The compound of Claim 6 wherein R¹ is selected from the group consisting of
5 chloro, fluoro and bromo.


8. The compound of Claim 7 wherein R¹ is chloro.

9. A pharmaceutical composition comprising the compound of Claim 6 and a
physiologically acceptable carrier or excipient.

10. A method for treating a disease characterized by pathogenic leukocyte
recruitment, pathogenic leukocyte activation or pathogenic leukocyte recruitment
and activation, comprising administering to a subject in need thereof an effective
amount of a compound of Claim 6.

11. The method of Claim 10 wherein R¹ chloro.
12. The method of Claim 10 wherein said disease is an acute or chronic inflammatory disease.
- 5 13. The method of Claim 10 wherein said disease is selected from the group consisting of inflammatory arthritis, inflammatory demyelinating disease, atherosclerosis, arteriosclerosis, restenosis, ischemia/reperfusion injury, diabetes mellitus, psoriasis, inflammatory bowel diseases, rejection of a transplanted graft, graft versus host disease, allergy and asthma.
- 10 14. The method of Claim 13 wherein said disease is inflammatory arthritis.
15. The method of Claim 14 wherein said inflammatory arthritis is rheumatoid arthritis.
16. The method of Claim 13 wherein said disease is inflammatory demyelinating disease.
- 15 17. The method of Claim 16 wherein said inflammatory demyelinating disease is multiple sclerosis.
18. A method of antagonizing a C-C Chemokine Receptor 1 in a subject, comprising administering to a subject in need thereof an effective amount of a compound of Claim 1.

19. A compound having the formula:



or a physiologically acceptable salt thereof, wherein R¹ is a halogen.

20. A pharmaceutical composition comprising the compound of Claim 19 and a
5 physiologically acceptable carrier or excipient.